Brenntag, the world's largest chemical distributor, is among a number of companies planning to float on the Frankfurt stock exchange in the next couple of weeks, kicking off the first wave of IPOs after the crisis.
German-based Brenntag, which started in 1874 as an egg trader in Berlin, aims to raise up to €837 million when it goes public on March 29. It plans to sell up to 10.5 million shares from a capital increase plus up to 4.45 million shares from existing shareholders at €46-56 apiece. The subscription period starts on Tuesday and will end on March 26. The proceeds will be used to pay down debt to increase its financial flexibility, Buchsteiner said.
Brenntag, which is owned by private equity group BC Partners, aims to pay out up to 45% of its net income to shareholders after its initial public offering later this month, it said on Tuesday.
We would expect to pay a dividend of 30-45% of net income after tax," Chief Financial Officer Juergen Buchsteiner told reporters at a news conference.
Brenntag is the only chemicals distributor with a global presence. It buys industrial and speciality chemicals in bulk from producers and delivers them in less-than-truckload quantities to makers of food, drugs and cosmetics, among others.
Chief executive Stephen Clark said he aimed to increase the company's market share of currently 6.9% through acquisitions worth a combined €100-150 million per year, which it could finance through its cash flow.
most read
Orion Announced Plans to Shut Down Carbon Black Plants
Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.
Roche and Zealand Pharma Collaborate on Weight Management Drug
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
Ineos Invests £30 Million to Slash Emissions at Hull Site by 75%
Ineos has completed a major £30 million investment at its Hull manufacturing site, converting the facility to run on clean-burning hydrogen instead of natural gas. This results in a 75% cut in carbon emissions.
Boehringer Ingelheim Paves the Way for Important Market Launches
Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.
Oxea Appoints Michael McHenry as New Chief Executive Officer
German oxo-chemicals manufacturer Oxea has appointed Michael McHenry as its new CEO with effect from August 15, 2025.